Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:6.4.1.1 (pyruvate carboxylase)
 1,516 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Activities of the 4 hepatic gluconeogenic enzymes: glucose-6-phosphatase, fructose-1,6-diphosphatase, pyruvate carboxylase, particulate and cytosolic phosphoenolpyruvate carboxykinase (PEPCK) have been measured in fetal rabbits (22, 25, 28, 30 and 31 days of gestation) and in fasted or suckling newborns (1 and 2 days after birth). Between days 25 and 31 of gestation, fructose 1,6-diphosphatase and particulate PEPCK activities represent 50% of adult (pregnant female) activities, while pyruvate carboxylase is present at adult values during the same period. Glucose-6-phosphatase is low and cytosolic PEPCK absent in fetal liver until 30 days of gestation and increase significantly during the day preceding birth. Al the enzymes show a further increase after birth independently of the nutritional status of the animals (starved or suckling).
 ...
PMID:Perinatal development of glucoeneogenic enzymes in rabbit liver. 22 57

Human blood platelets contain no detectable activity of the enzymes fructose diphosphatase (EC 3.1.3.11), phospho-enolpyruvate carboxykinase (EC 4.1.1.32) and pyruvate carboxylase (EC 6.4.1.1.). Glucose-6-phosphatase (EC 3.1.3.9) activity is very low. Phosphofructokinase present in human blood platelets, catalyzes a reaction which can be stimulated by AMP in a platelet homogenate, due to the presence of endogenous ADP and myokinase. These enzymes are responsible for the formation of fructose-6-phosphate from fructose-1, 6-diphosphate. Pyruvate kinase (EC 2.7.1.40) in human blood platelets belongs to the M-type, which is not inhibited by ATP, at least not under the conditions applied. The results obtained indicate that gluconeogenesis in human blood platelets is not present in the way which has been established for liver and kidney.
 ...
PMID:Insignificance of gluconeogenesis in human blood platelets. 112 26

Male Sprague-Dawley rats were injected intraperitoneally with 0, 0.25, 0.75 and 1.25 mg/kg/day for 14 days. At the end of 7 and 14 days treatment period, body weight gain, serum protein, serum glucose, serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) were measured. Glucose-6-phosphatase (G6-Pase), fructose-1, 6-di-phosphatase (FD-Pase), phosphoenol pyruvate carboxykinase (PEPCK) and pyruvate carboxylase (PC) in kidney and liver were determined. A significant decrease in body weight gain in rats treated with 1.25 mg cadmium for 7 and 14 days was observed. Serum glucose, serum protein, SGOT and SGPT were increased in cadmium treated rats. A significant increase in all four key gluconeogenic enzymes were observed in both kidney and liver tissues of rats treated with cadmium. The results of this study suggest that cadmium induces gluconeogenesis which is dose and time dependent.
 ...
PMID:Effect of intraperitoneally injected cadmium on renal and hepatic gluconeogenic enzymes in rats. 715 23